Roivant Launches Phase 2b/3 Brepocitinib Trial In Lichen Planopilaris As Batoclimab Fails Primary Endpoint In Phase 3 Thyroid Eye Disease Studies

Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIV

0.00

Roivant Launches Phase 2b/3 Brepocitinib Trial In Lichen Planopilaris As Batoclimab Fails Primary Endpoint In Phase 3 Thyroid Eye Disease Studies